Demcizumab: Additional Phase Ib data

Data from 32 previously untreated patients with advanced pancreatic cancer in an open-label, dose-escalation, international Phase Ib trial showed that first-line treatment with IV demcizumab plus gemcitabine and Abraxane nab-paclitaxel led a median PFS of 7.1 months and a median overall survival (OS) of 12.7 months. In 28 evaluable patients, the clinical benefit rate (CBR) was 89%, including 14 partial responses. Data were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco. OncoMed has previously reported data from the trial (see BioCentury, Nov. 4, 2013; Jan. 20, 2014 & Nov. 24, 2014). ...